Gland Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.71×	0.70×	0.66×	0.68×	0.74×
	1.20×	1.21×	1.19×	1.15×	1.20×
	19.6%	18.8%	15.9%	17.5%	24.2%
	0.54×	0.54×	0.51×	0.58×	0.44×
	1.21×	1.21×	1.23×	1.22×	1.10×
	10.9%	10.4%	7.8%	9.7%	10.5%
	10.5%	10.5%	7.8%	9.3%	10.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAND₹2,815.00

Gland Pharma Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB AUROPHARMA PPLPHARMA SYNGENE WOCKPHARMA ASTERDM COHANCE LALPATHLABMcap ₹46,380 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.68	0.66	0.70	0.71
Interest Burden (Pretax/EBIT) ×	1.20	1.15	1.19	1.21	1.20
EBIT Margin %	24.22	17.45	15.86	18.75	19.59
Asset Turnover ×	0.44	0.58	0.51	0.54	0.54
Financial Leverage (Assets/Equity) ×	1.10	1.22	1.23	1.21	1.21
ROE (5-step product, year-end total equity) %	10.46	9.67	7.78	10.42	10.95
ROE (owners' profit / average owners' equity) %	10.33	9.26	7.82	10.53	10.53

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.